Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys: In vivo and in vitro studies

Drug Metabolism and Disposition

Volumn 24, Issue 11, 1996, Pages 1263-1271

  Prueksaritanont, Thomayant ^a   Gorham, Lynn M ^a   Ellis, Joan D ^a   Fernandez Metzler, Carmen ^a   Deluna, Polly ^a   Gehret, John R ^a   Strong, Kristie L ^a   Hochman, Jerome H ^a   Askew, Ben C ^a   Duggan, Mark E ^a   Gilbert, John D ^a   Lin, Jiunn H ^a   Vyas, Kamlesh P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; L 742998; L 751164; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TRANSPORT; INTRAVENOUS DRUG ADMINISTRATION; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PORTAL VEIN; PRIORITY JOURNAL; RAT; RHESUS MONKEY; SMALL INTESTINE; SPECIES DIFFERENCE;

ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; DOGS; HUMANS; INTESTINES; LIVER; MACACA MULATTA; MALE; PRODRUGS; PYRIDINES; SPECIES SPECIFICITY; TISSUE DISTRIBUTION;

ANIMALIA; CANIS FAMILIARIS; MACACA MULATTA;

EID: 8044245473     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. L. P. Balant, E. Doelker, and P. Buri: Prodrugs for the improvement of drug absorption via different routes of administration. Eur. J. Drug Metab. Pharmacokinet. 15, 143-153 (1990).
2. R. E. Notari: Prodrug design. Pharmacol Ther. 14, 25-53 (1981).
3. N. F. H. Ho, J. Y. Park, W. Morozowich, and W. I. Higuchi: Physical model approach to design of drugs with improved intestinal absorption. In "Design of Biopharmaceutical Properties through Prodrugs and Analogs" (E. B. Roche, ed.), pp. 201-227. American Pharmaceutical Association Academy of Pharmaceutical Sciences, Washington, D.C., 1977.
4. M. Ehrnebo, S. Nilsson, and L. O. Boreus: Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man. J. Pharmacokinet. Biopharm. 7, 429-451 (1979).
5. E. H. Ulm, M. Hichens, H. J. Gomez, A. E. Till, E. Hand, T. C. Vassil, J. Biollaz, H. R. Brunner, and J. L. Schelling: Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br. J. Clin. Pharmacol. 14, 357-362 (1982).
6. S. M. Singhvi, K. L. Duchin, R. A. Morrison, D. A. Willard, D. W. Everett, and M. Frantz: Disposition of fosinopril sodium in healthy subjects. Br. J. Clin. Pharmacol 25, 9-15 (1988).
7. J. A. Zablocki, F. S. Tjoeng, P. R. Bovy, M. Miyano, R. B. Garland, K. Williams, L. Schretzman, M. E. Zupec, J. G. Rico, R. J. Lindmark, M. V. Toth, D. E. McMackins, S. P. Adams, S. G. Panzer-Knodle, N. S. Nicholson, B. B. Taite, A. K. Salyers, L. W. King, J. G. Campion, and L. P. Feigen: A novel series of orally active antiplatelet agents. Bioorgan. Med. Chem. 3, 539-551 (1995).
8. G. L. Amidon, R. S. Pearlman, and G. D. Leesman: Design of prodrugs through consideration of enzyme-substrate specificities. In "Design of Biopharmaceutical Properties through Prodrugs and Analogs" (E. B. Roche, ed.), pp. 281-315. American Pharmaceutical Association Academy of Pharmaceutical Sciences, Washington, D.C., 1977.
9. A.M. Kahns, A. Buur, and H. Bundgaard: Prodrugs of peptides. 18. Synthesis and evaluation of various esters of desmopressin (dDAVP). Pharmacol. Res. 10, 68-74 (1993).
10. F.-J. Leinweber: Possible physiological roles of carboxylic ester hydrolases. Drug Metab. Rev. 18, 379-439 (1987).
11. F. M. Williams: Clinical significance of esterases in man. Clin. Pharmacokinet. 10, 392-403 (1985).
12. W. H. Barr and S. Riegelman: Intestinal drug absorption and metabolism. I. Comparison of methods and models to study physiological factors of in vitro and in vivo intestinal absorption. J. Pharm Sci. 59, 154-163 (1970).
13. T. Prueksaritanont, L. M. Dwyer, and A. E. Cribb: (+)-Bufuralol 1′-hydroxylase activity in human and rhesus monkey intestine and liver. Biochem. Pharmacol. 50, 1521-1525 (1995).
14. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275 (1951).
15. L. Z. Benet and R. L. Galeazzi: Noncompartmental determination of the steady-state volume of distribution. J. Pharm. Sci. 68, 1071-1074 (1979).
16. M. F. Hebert, J. P. Roberts, T. Prueksaritanont, and L. Z. Benet: Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther. 52, 453-457 (1992).
17. A. Rane, G. R. Wilkinson, and D. G. Shand: Prediction of hepatic extraction from in vitro measurement of intrinsic clearance. J. Pharmacol. Exp. Ther. 200, 420-424 (1977).
18. T. Prueksaritanont, S. K. Balani, L. M. Dwyer, J. D. Ellis, L. R. Kauffman, S. L. Varga, S. M. Pitzenberger, and A. D. Theoharides: Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372: in vivo and in vitro studies in rats, dogs, monkeys, and humans. Drug Melab. Dispos. 23, 688-695 (1995).
19. M. Rowland and T. N. Tozer: "Clinical Pharmacokinetics: Concepts and Applications," pp. 367-393. Williams & Wilkins, Baltimore, MD, 1995.
20. D. J. Ecobichon: Relative amounts of hepatic and renal carboxylesterase in mammalian species. Res. Commun. Chem. Pathol. Pharmacol. 3, 629-636 (1972).
21. T. Prueksaritanont, L. M. Gorham, J. Hochman, L. Trans, and K. P. Vyas: Comparative studies of drug metabolizing enzymes in dog, monkey and human small intestines and in Caco-2 cells. Drug Metab. Dispos. 24, 634-642 (1996).
22. J.B. Houston: Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47, 1469-1479 (1994).
23. H. Boxenbaum: Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J. Pharmacokinet. Biopharmacol. 8, 165-176 (1980).
24. A. R. Hilgers, R. A. Conradi, and P. S. Burton: Caco-2 cell monolayer as a model for drug transport across the intestinal mucosa. Pharmacol. Res. 7, 902-910 (1990).
25. P. Artursson and J. Karlsson: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175, 880-885 (1991).
26. J. Banchard and L. M. Tang: Reevaluation of the absorption of carbenoxolone using an in situ rat intestinal technique. J. Pharm. Sci. 79, 411-414 (1990).
27. M. D. Ribadeneira, B. J. Aungst, C. J. Eyermann, and S.-M. Huang: Effects of structural modifications on the intestinal permeability of angiotensin II receptor antagonists and the correlation of in vitro, in situ, and in vivo absorption. Pharm. Res. 13, 227-233 (1996).
28. P. J. M. Klippert and J. Noordhoek: The area under the curve of metabolites for drugs and metabolites cleared by the liver and extrahepatic organs. Drug Metab. Dispos. 13, 97-101 (1985).